Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.
Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...
When her consultant offered 20st Sarah a brand new injection called Ozempic that promised to treat her diabetes and help her ...
A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...
Spending on older medicines like metformin, used only for diabetes, declined. But that of popular GLP-1 drugs such as Novo ...
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.
If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...
Medical treatments, including jabs used for weight loss, are monitored in part using the Medicines and Healthcare products ...
The other day I went to see a plastic surgeon who just happens to be Beverly Hills' best-kept secret. You won't find him on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback